{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:31:07Z","timestamp":1755217867236,"version":"3.43.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clml.2025.03.017","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T02:14:07Z","timestamp":1743905647000},"page":"e591-e599.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8115-7322","authenticated-orcid":false,"given":"Kelsey","family":"Baron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4971-949X","authenticated-orcid":false,"given":"Eric","family":"Anto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Esther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-1295","authenticated-orcid":false,"given":"Victoria A.","family":"Vardell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3174-8877","authenticated-orcid":false,"given":"Allison","family":"Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Ermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5988-2878","authenticated-orcid":false,"given":"Lindsey A.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9848-9497","authenticated-orcid":false,"given":"Boyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6054-5238","authenticated-orcid":false,"given":"Harsh R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2025.03.017_bib0001","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.03.017_bib0002","unstructured":"National Comprehensive Cancer Network. B-cell lymphomas (Version 6.2023) https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed November 19, 2023."},{"issue":"19","key":"10.1016\/j.clml.2025.03.017_bib0003","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.03.017_bib0004","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9873","key":"10.1016\/j.clml.2025.03.017_bib0005","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"9873","key":"10.1016\/j.clml.2025.03.017_bib0006","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clml.2025.03.017_bib0007","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00277-016-2668-0","article-title":"Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study","volume":"95","author":"Mondello","year":"2016","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.clml.2025.03.017_bib0008","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3390\/cancers16071285","article-title":"Comparing R-Bendamustine vs. R-CHOP plus maintenance therapy as first-line systemic treatment in follicular lymphoma: a multicenter Retrospective GELTAMO study","volume":"16","author":"Bastos-Oreiro","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2025.03.017_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1120009X.2022.2043512","article-title":"BR (bendamustine plus rituximab) versus R-CHOP for patients with indolent B-cell lymphomas: a systematic review and meta-analysis","volume":"35","author":"Ou","year":"2023","journal-title":"J Chemother"},{"issue":"8","key":"10.1016\/j.clml.2025.03.017_bib0010","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2023.2214651","article-title":"Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP","volume":"64","author":"Nichols","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.clml.2025.03.017_bib0011","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3324\/haematol.2019.230649","article-title":"Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma","volume":"105","author":"Strati","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2025.03.017_bib0012","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjh.18831","article-title":"Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan","volume":"202","author":"Jo","year":"2023","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2025.03.017_bib0013","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2025.03.017_bib0014","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.03.017_bib0015","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdl039","article-title":"Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group experience","volume":"17","author":"Ganti","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.03.017_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1120967","article-title":"Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: results of a retrospective study from the Fondazione Italiana Linfomi","volume":"13","author":"Margiotta-Casaluci","year":"2023","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.clml.2025.03.017_bib0017","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clml.2018.11.010","article-title":"Multicenter analysis of advanced stage grade 3A follicular lymphoma outcomes by frontline treatment regimen","volume":"19","author":"Shah","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.clml.2025.03.017_bib0018","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00277-020-04171-7","article-title":"First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis","volume":"99","author":"Pouyiourou","year":"2020","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.03.017_bib0019","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1634\/theoncologist.2017-0037","article-title":"Bendamustine plus Rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a multicenter, retrospective study","volume":"23","author":"Mondello","year":"2018","journal-title":"Oncologist"},{"issue":"9759","key":"10.1016\/j.clml.2025.03.017_bib0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2025.03.017_bib0021","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjh.15720","article-title":"Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma","volume":"184","author":"Hill","year":"2019","journal-title":"Br J Haematol"},{"issue":"31","key":"10.1016\/j.clml.2025.03.017_bib0022","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results for the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.03.017_bib0023","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"for the FLASH (Follicular Lymphoma Analysis of Surrogacy Hypothesis) Group, validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.03.017_bib0024","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/cancers15030785","article-title":"Follicular lymphoma in the 5theEdition of the WHO-classification of haematolymphoid neoplasms-updated classification and new biological data","volume":"15","author":"Kurz","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.clml.2025.03.017_bib0025","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1097\/HS9.0000000000000919","article-title":"Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study","volume":"7","author":"Townsend","year":"2023","journal-title":"Hemasphere"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:25:14Z","timestamp":1754429114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2152265025001119"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}